Collectively, these data identify brigatinib as a direct and potent inhibitor of multiple kinases, including FAK1 (PTK2) and FAK2 (PTK2B), and novel targets, GAK and TNK2, in both arachnoid and schwannoma cells. Here, PTK2 is linked to schwannoma.